Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases

Olivia M. Lucero, Ji-Ann Lee, Jenna Bowman, Kara Johnson, Gopal Sapparapu, John K. Thomas, Guang Fan, Bill H. Chang, Karina Thiel-Klare, Christopher A. Eide, Craig Okada, Mike Palazzolo, Evan Lind, Yoko Kosaka, Brian J. Druker, Nicholas Lydon, Peter M. Bowers

Clin Cancer Res (2023) 29 (20): 4230–4241.

https://doi.org/10.1158/1078-0432.CCR-22-0906

Published: 13 October 2023

View article titled, Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases

Includes: Supplementary data

Journal Articles

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Monika A. Davare, Jacob J. Henderson, Anupriya Agarwal, Jacob P. Wagner, Sudarshan R. Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W. Gilheeney, Ana DeCarvalo, Tom Mikkelson, Erwin G. Van Meir, Marc Ladanyi, Brian J. Druker

Clin Cancer Res (2018) 24 (24): 6471–6482.

https://doi.org/10.1158/1078-0432.CCR-18-1052

Published: 13 December 2018

View article titled, Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Includes: Multimedia, Supplementary data

Journal Articles

Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes

Stephen E. Kurtz, Beth Wilmot, Shannon McWeeney, Avanish Vellanki, Andrea Local, Khalid Benbatoul, Peter Folger, Susan Sheng, Hongying Zhang, Stephen B. Howell, William G. Rice, Brian J. Druker, Jeffrey W. Tyner

Clin Cancer Res (2017) 23 (24_Supplement): 44.

https://doi.org/10.1158/1557-3265.HEMMAL17-44

Published: 14 December 2017

View article titled, Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes

Journal Articles

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, Monika A. Davare

Clin Cancer Res (2016) 22 (10): 2351–2358.

https://doi.org/10.1158/1078-0432.CCR-15-2013

Published: 12 May 2016

View article titled, A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <em>ROS1</em>-Rearranged Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract B36: Induction of IL-6 by breast cancer chemotherapy mediates loss of fat-free lean body mass in tumor-free mice by decreasing systemic IGF-1

Lisa J. Wood, Collin R. Elsea, Lillian M. Nail, Kerri A. Winters, Brian J. Druker

Clin Cancer Res (2010) 16 (7_Supplement): B36.

https://doi.org/10.1158/1078-0432.TCME10-B36

Published: 02 February 2016

View article titled, Abstract B36: Induction of IL-6 by breast cancer chemotherapy mediates loss of fat-free lean body mass in tumor-free mice by decreasing systemic IGF-1

Journal Articles

Abstract B35: Serum inflammatory biomarkers of acute and persistent fatigue in a preclinical breast cancer treatment model

Lisa J. Wood, Lillian M. Nail, Collin R. Elsea, Brian J. Druker

Clin Cancer Res (2010) 16 (7_Supplement): B35.

https://doi.org/10.1158/1078-0432.TCME10-B35

Published: 02 February 2016

View article titled, Abstract B35: Serum inflammatory biomarkers of acute and persistent fatigue in a preclinical breast cancer treatment model

Journal Articles

A novel, high-throughput assay for detection of ABL T315I mutations

Michael C. Heinrich, Jason R. Morich, Emmanuel J. Beillard, Courtney Fuller, Chad D. Galderisi, Brian J. Druker

Clin Cancer Res (2006) 12 (19_Supplement): B68.

Published: 15 August 2014

View article titled, A novel, high-throughput assay for detection of ABL T315I mutations

Journal Articles

Progressive loss of EGFR in a subpopulation of breast cancers: Implications in target-directed therapeutics

Lee Yee Choong, Simin Lim, Marie Chiew-Shia Loh, Xiaohui Man, Yunhao Chen, Weiyi Toy, Mengfei Pan, Chien-Shing Chen, Anuradha Poonepalli, M Prakash Hande, Puay Hoon Tan, Manuel Salto-Tellez, Chow-Yin Wong, Nilesh Shah, Brian J Druker, Yoon-Pin Lim

Clin Cancer Res (2007) 13 (22_Supplement): B33.

Published: 15 August 2014

View article titled, Progressive loss of EGFR in a subpopulation of breast cancers: Implications in target-directed therapeutics

Journal Articles

Novel tyrosine phosphorylation targets of EGF signaling and gefitinib in human cancer cells.

Yunhao Chen, Teck Yew Low, Lee Yee Choong, Rajarshi Ray, Yee Ling Tan, Weiyi Toy, Qingsong Lin, Boon Keong Ang, Chee Hong Wong, Simin Lim, Bin Li, Choy Leong Hew, Newman Siu-Kwan Sze, Brian J. Druker, Yoon Pin Lim

Clin Cancer Res (2007) 13 (22_Supplement): B64.

Published: 15 August 2014

View article titled, Novel tyrosine phosphorylation targets of EGF signaling and gefitinib in human cancer cells.

Journal Articles

Differential expression of novel tyrosine kinase substrates during breast cancer development

Yunhao Chen, Lee Yee Choong, Qingsong Lin, Robin Philps, Chee Hong Wong, Boon Keong Ang, Marie Chiew Shia Loh, Choy Leong Hew, Nilesh Shah, Brian J Druker, Poh Kuan Chong, Yoon Pin Lim

Clin Cancer Res (2007) 13 (22_Supplement): B48.

Published: 15 August 2014

View article titled, Differential expression of novel tyrosine kinase substrates during breast cancer development

Journal Articles

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey W. Tyner, Rosalie Sears, Michael P. Vitek, María D. Odero, Dale J. Christensen, Brian J. Druker

Clin Cancer Res (2014) 20 (8): 2092–2103.

https://doi.org/10.1158/1078-0432.CCR-13-2575

Published: 15 April 2014

View article titled, Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

Thomas O'Hare, Michael W.N. Deininger, Christopher A. Eide, Tim Clackson, Brian J. Druker

Clin Cancer Res (2011) 17 (2): 212–221.

https://doi.org/10.1158/1078-0432.CCR-09-3314

Published: 16 January 2011

View article titled, Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

Journal Articles

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

Richard D. Press, Chad Galderisi, Rui Yang, Carole Rempfer, Stephanie G. Willis, Michael J. Mauro, Brian J. Druker, Michael W.N. Deininger

Clin Cancer Res (2007) 13 (20): 6136–6143.

https://doi.org/10.1158/1078-0432.CCR-07-1112

Published: 18 October 2007

View article titled, A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

Journal Articles

Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

Paul La Rosée, Taiping Jia, Shadmer Demehri, Nicolai Härtel, Peter de Vries, Lynn Bonham, David Hollenback, Jack W. Singer, Junia V. Melo, Brian J. Druker, Michael W. Deininger

Clin Cancer Res (2006) 12 (21): 6540–6546.

https://doi.org/10.1158/1078-0432.CCR-06-0140

Published: 03 November 2006

View article titled, Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

Includes: Supplementary data

Journal Articles

Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl⁺ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate

Tri K. Nguyen, Mohamed Rahmani, Ning Gao, Lora Kramer, Amie S. Corbin, Brian J. Druker, Paul Dent, Steven Grant

Clin Cancer Res (2006) 12 (7): 2239–2247.

https://doi.org/10.1158/1078-0432.CCR-05-2282

Published: 11 April 2006

View article titled, Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl<sup>+</sup> Leukemia Cells Sensitive and Resistant to Imatinib Mesylate

Journal Articles

Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib

Thomas O'Hare, Denise K. Walters, Eric P. Stoffregen, Daniel W. Sherbenou, Michael C. Heinrich, Michael W.N. Deininger, Brian J. Druker

Clin Cancer Res (2005) 11 (19): 6987–6993.

https://doi.org/10.1158/1078-0432.CCR-05-0622

Published: 03 October 2005

View article titled, Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib

Journal Articles

Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs

Yoon-Pin Lim, Chow Yin Wong, London Lucien Ooi, Brian J. Druker, Richard J. Epstein

Clin Cancer Res (2004) 10 (12): 3980–3987.

https://doi.org/10.1158/1078-0432.CCR-03-0663

Published: 24 June 2004

View article titled, Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: <subtitle>Implications for Adjuvant Use of Kinase-Inhibitory Drugs</subtitle>

NARROW

Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Abstract B36: Induction of IL-6 by breast cancer chemotherapy mediates loss of fat-free lean body mass in tumor-free mice by decreasing systemic IGF-1

Abstract B35: Serum inflammatory biomarkers of acute and persistent fatigue in a preclinical breast cancer treatment model

A novel, high-throughput assay for detection of ABL T315I mutations

Progressive loss of EGFR in a subpopulation of breast cancers: Implications in target-directed therapeutics

Novel tyrosine phosphorylation targets of EGF signaling and gefitinib in human cancer cells.

Differential expression of novel tyrosine kinase substrates during breast cancer development

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl⁺ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate

Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib

Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only